

The DNA probe market is still very small and now at a development stage as described in Appendix 2-14). Major market development plans by major companies are mentioned below:

<u>Business name</u>	<u>In cooperation with</u>	<u>Products marketed</u>	<u>Future trends</u>
Toray, Toray, Fuji- Bionics	Life Technology (U.S.) Product import, clinical study facility Juntendo University Dept. of Obstetrics and Gynecology Juntendo Urayasu Hospital Chiba University Dept. of Obstetrics and Gynecology Chiba University 1st Dept. of Micro- biology Eucaryotic Microbiology Research Center Chiba Prefectural Anticancer Society	HPV screening By the gross, 6, 11, 16, 18,31, 33 and 35 types are detected. Label is ³² P.	1) HPV kits will be used to check specimens that have been evaluated as false-negative in cell diagnoses. Consequently, they will become popular for screening. 2) Potential markets will be regarded as 3,000,000 studies in combination with specimens of mass screening and diagnostics 3) Since ³² P is used as the label the facilities used are limited to large study centres and university hospitals. 4) The insurance score is estimated at 1,000 points. 5) Permission to import probes that can type individuals from gross detections will be applied for in the fall of 1989. 6) Studies are now being performed on changing from ³² P to ¹²⁵ I as the label and on NONRIA substances. 7) Of the diagnoses of infectious disease, non-A-non-B hepatitis virisus marketable and future trends include a demand for analysis and diagnosis of human genes.
Chugai Seiyaku	Gen-Probe(U.S.) Product import \$2,700,000 paid for research and development (more than 378,000,000)	Tissue Culture Mycoplasma kit marketed for re- search in Decem- ber 1988. It is estimated that 5 products for mycoplasma,	1) The items that will be marketed in the future will all be marketed as <u>in-vitro</u> diagnostic drugs. Candidates for marketing in less than 2 to 3 years have already increased to 18 items.